Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival
- 26 July 2013
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 65 (6), 1191-1197
- https://doi.org/10.1016/j.eururo.2013.07.006
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent ReportingJournal of Clinical Oncology, 2012
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate CancerThe American Journal of Pathology, 2011
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- BioGPS: an extensible and customizable portal for querying and organizing gene annotation resourcesGenome Biology, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cellsOncogene, 2008
- TiGER: A database for tissue-specific gene expression and regulationBMC Bioinformatics, 2008